Oruka Therapeutics (NASDAQ:ORKA) Shares Down 4.3% - Time to Sell?

Key Points

• Oruka Therapeutics shares fell 4.3% to about $80.78, with trading volume down 97% from the average session. The company has a $5.33 billion market capitalization and trades below its 50-day moving average.
• Analyst sentiment remains broadly positive despite one recent downgrade: ten analysts rate the stock a Buy and one rates it a Sell, producing a “Moderate Buy” consensus and an average price target of $128.91.
• The company reported a quarterly loss of $0.55 per share, missing estimates by $0.04, while insiders sold $13.6 million of shares over the past 90 days. Oruka is a clinical-stage biotech developing long-acting antibody treatments for immune-mediated diseases.

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report)'s stock price was down 4.3% during mid-day trading on Tuesday. The stock traded as low as $81.90 and last traded at $80.7750. Approximately 32,656 shares were traded during trading, a decline of 97% from the average session volume of 1,091,635 shares. The stock had previously closed at $84.38.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on ORKA shares. Wall Street Zen lowered shares of Oruka Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, August 16th. Weiss Ratings raised shares of Oruka Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday, July 15th. BTIG Research reissued a "buy" rating and issued a $151.00 price target on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Wedbush set a $120.00 price objective on shares of Oruka Therapeutics in a report on Thursday, September 24th. Finally, Guggenheim restated a "buy" rating and issued a $200.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Oruka Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $128.91.

Oruka Therapeutics Trading Down 4.7%

The firm has a market cap of $5.33 billion, a price-to-earnings ratio of -39.53 and a beta of -0.37. The company has a fifty day moving average price of $95.65 and a 200-day moving average price of $78.01.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.04). As a group, research analysts forecast that Oruka Therapeutics, Inc. will post -2.42 earnings per share for the current fiscal year.

Insider Activity at Oruka Therapeutics

In other Oruka Therapeutics news, SVP Arjun Agarwal sold 10,000 shares of the stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $106.66, for a total transaction of $1,066,600.00. Following the transaction, the senior vice president owned 15,312 shares in the company, valued at approximately $1,633,177.92. This represents a 39.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Klein sold 75,000 shares of the business's stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $91.83, for a total value of $6,887,250.00. Following the completion of the sale, the chief executive officer owned 925,580 shares of the company's stock, valued at $84,996,011.40. This trade represents a 7.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 147,950 shares of company stock worth $13,619,306 in the last 90 days. Corporate insiders own 23.49% of the company's stock.

Hedge Funds Weigh In On Oruka Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Nykredit A S acquired a new position in shares of Oruka Therapeutics during the 2nd quarter worth about $29,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Oruka Therapeutics during the fourth quarter valued at approximately $67,000. Orion Capital Management LLC acquired a new position in shares of Oruka Therapeutics during the second quarter valued at approximately $91,000. Royal Bank of Canada lifted its position in shares of Oruka Therapeutics by 178.5% in the first quarter. Royal Bank of Canada now owns 3,172 shares of the company's stock valued at $155,000 after acquiring an additional 2,033 shares in the last quarter. Finally, PNC Financial Services Group Inc. lifted its position in shares of Oruka Therapeutics by 119.7% in the first quarter. PNC Financial Services Group Inc. now owns 3,186 shares of the company's stock valued at $156,000 after acquiring an additional 1,736 shares in the last quarter. 56.44% of the stock is currently owned by institutional investors and hedge funds.

About Oruka Therapeutics

Oruka Therapeutics, Inc NASDAQ: ORKA is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company's approach is designed to extend the duration of treatment and potentially reduce the frequency of dosing for patients with chronic inflammatory conditions.

Oruka's pipeline includes ORKA-001 and ORKA-002, next-generation monoclonal antibodies targeting interleukin-23 (IL-23), a cytokine involved in several autoimmune and inflammatory diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.